LENZ Therapeutics (NASDAQ:LENZ) Given New $29.00 Price Target at Bank of America

LENZ Therapeutics (NASDAQ:LENZ) had its price target dropped by investment analysts at Bank of America from $35.00 to $29.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s price objective would indicate a potential upside of 216.70% from the stock’s current price.

LENZ has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research report on Monday, December 15th. William Blair restated an “outperform” rating on shares of LENZ Therapeutics in a research report on Tuesday, March 10th. Finally, Wall Street Zen downgraded shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, LENZ Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $50.20.

LENZ Therapeutics Stock Performance

Shares of LENZ Therapeutics stock opened at $9.16 on Wednesday. The company has a market capitalization of $286.52 million, a P/E ratio of -4.35 and a beta of 0.52. LENZ Therapeutics has a 1 year low of $8.85 and a 1 year high of $50.40. The company’s fifty day moving average is $14.33 and its two-hundred day moving average is $24.51.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.25). The firm had revenue of $1.59 million for the quarter, compared to analyst estimates of $3.09 million. As a group, equities analysts expect that LENZ Therapeutics will post -2.18 earnings per share for the current year.

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in shares of LENZ Therapeutics during the 3rd quarter worth approximately $27,000. Bfsg LLC acquired a new position in shares of LENZ Therapeutics in the third quarter worth $30,000. State of Wyoming purchased a new stake in shares of LENZ Therapeutics in the fourth quarter valued at $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of LENZ Therapeutics during the fourth quarter valued at $32,000. Finally, Osaic Holdings Inc. increased its position in LENZ Therapeutics by 2,146.2% during the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock worth $34,000 after purchasing an additional 1,116 shares in the last quarter. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

More LENZ Therapeutics News

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: Management says the newly launched LNZ100 has exceeded commercial expectations and positions the company for a larger market opportunity, which could support future revenue upside. LENZ Therapeutics Surpasses Expectations with LNZ100 Launch
• Positive Sentiment: Company highlighted a strong cash position and outlined an acceleration strategy for 2026 on the earnings call, which may provide runway for commercialization and R&D investments. LENZ Q4 2025 Earnings Call Highlights
• Positive Sentiment: LENZ is expanding its VIZZ sales force to 117 reps, a concrete commercial investment that could help convert product demand into sales over coming quarters. Lenz expands VIZZ sales force
• Neutral Sentiment: The full Q4 earnings call transcript and company press release are available for review (useful for detail on guidance, cash runway and commercialization cadence). Earnings Call Transcript
• Neutral Sentiment: Multiple short-interest reports show zero shares / NaN changes and a 0.0 days-to-cover metric — this appears to be data noise rather than meaningful short activity, so it is unlikely to explain today’s move.
• Negative Sentiment: Q4 results missed: EPS of ($1.16) vs. consensus ($0.91) and revenue $1.59M versus $3.09M expected — the earnings and revenue shortfall is the primary near‑term catalyst pushing the stock lower. Q4 loss, misses revenue estimates
• Negative Sentiment: Market reports note shares hit an all‑time low after the underwhelming 4Q sales report, which can trigger additional selling and weigh on investor sentiment. Shares hit all-time low
• Negative Sentiment: Technically the stock is trading well below its 50‑day ($14.33) and 200‑day ($24.51) moving averages and near its 52‑week low, magnifying downside pressure until clarity on sales trajectory and revenue growth is delivered.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.